Phase 3 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have not previously received chemotherapy, radiation therapy, or any other anti-cancer treatment
- People aged between 18 and 80 years old
- Men, or women who are not pregnant or breastfeeding
- People who have been confirmed by tissue testing to have stomach adenocarcinoma (a specific type of stomach cancer) and for whom keyhole (laparoscopic or robotic) surgery to remove the stomach cancer is planned
- People whose cancer has grown to a certain depth in the stomach wall (T3 stage or deeper) with no spread to distant parts of the body, and whose cancer meets the surgical requirements for a specific type of keyhole surgery called laparoscopic D2 radical resection
- People whose expected survival is more than 6 months
- People who have had previous surgery outside the abdomen, or who have had keyhole gallbladder removal surgery (confirm with trial site for exact interpretation)
- People whose blood test results show healthy bone marrow function, with white blood cell count, neutrophil count, platelet count, and haemoglobin all within acceptable ranges
- People whose liver and kidney function blood tests fall within acceptable limits
- People with a good general physical activity level, rated 0–1 on the ECOG performance scale (a medical scoring system for daily functioning)
- People rated as ASA Grade I–III before surgery (a standard medical rating of overall health before an operation)
- People who are willing to sign an informed consent form
Who may not be able to join:
- People whose CT or MRI scan shows significantly enlarged lymph nodes — specifically, at least one lymph node measuring 3 cm or more, or three neighbouring lymph nodes each measuring 1.5 cm or more
- Women who are pregnant or breastfeeding
- People who have had another type of cancer within the past 5 years
- People who have a temperature of 38°C or higher before the operation, or who have an active infection requiring treatment
- People with a serious mental health condition
- People with severe lung disease, where breathing test results show lung function below 50% of expected
- People with severe liver or kidney problems, including liver enzyme levels more than twice the normal limit
- People who have had unstable chest pain (angina) or a heart attack within the past 6 months
- People who have had a stroke or brain bleed within the past 6 months (not including old, previously healed strokes — confirm with trial site)
- People who have taken steroid medications (glucocorticoids) throughout their whole body within the past month
- People whose stomach cancer has caused an emergency complication such as bleeding, a hole in the stomach wall, or a blockage requiring urgent surgery
- People who have participated in another clinical trial within the past 6 months or are currently in one
- People in whom internal spread of cancer within the abdomen has been confirmed through keyhole examination, tissue sampling, or fluid testing
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yanbing Zhou, MD, The Affiliated Hospital of Qingdao University
Phone: 86532-82911324
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
5-years Recurrence-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.